Fill out the form and Download the Product Brief


Fill out the form and Download White Paper


Fill the form and Download the Ebook

In this eBook, Brandon Hall Group explains not only the importance of compliance training but also how to develop a strategy that effectively develops your workforce, mitigates risk, meets regulatory requirements and drives business outcomes.


Qstream Awarded €30,000 Prize in the Ascensia Diabetes Challenge

22nd June 2018


Qstream microlearning solution recognized for it’s proven impact on helping to control glucose Levels in patients with Type 2 diabetes


BURLINGTON, Mass. – June 22, 2018 – Qstream, makers of software that uses science, data, and mobile technology to prompt meaningful behavior change, today announced the company has been named a runner up in the Ascensia Diabetes ChallengeThe Ascensia Diabetes Challenge is a global innovation competition focused on finding innovative digital solutions to support type 2 diabetes management. With this honor, Qstream was awarded a cash prize of €30,000 (approximately $34,700) in recognition of its proven capabilities to help people with type 2 diabetes better manage glucose levels.

Qstream is a scientifically proven microlearning solution initially developed at Harvard Medical School by Qstream founder, Dr. B. Price Kerfoot, which prompts meaningful behavior change in people. For patients with type 2 diabetes, a recent clinical study found patients who were randomly assigned to use Qstream had significantly greater reductions in hemoglobin A1c (HbA1c), a common measure of long-term blood glucose control, than their counterparts who received the identical content in a booklet format.

“Through more than 20 scientific trials, Qstream has been consistently proven to drive strong participant engagement and improve outcomes,” said Dr. Kerfoot, MD EdM. “Our diabetes-specific Qstream challenge, designed to guide patients on self-management of diabetes, delivered reductions in blood glucose comparable to starting a new diabetes medication among patients with poor blood sugar control.”

“To know that Qstream positively impacts the lives of people with type 2 diabetes is very rewarding,” said Rich Lanchantin, CEO of Qstream. “Qstream will contribute the prize money to Dr. Kerfoot’s groundbreaking research in this important area. We are delighted the team at the Ascensia Diabetes Challenge sees the value of our solution.”


About Qstream
Developed at Harvard Medical School, Qstream is clinically proven in more than 20 scientific trials to boost retention and durably change clinical practice patterns to improve patient outcomes. Leading medical centers, teaching schools and CME providers around the globe rely on Qstream to reinforce education on hospital-acquired conditions, value-based purchasing and HCAHPS, readmissions and transitions of care, patient safety, and more. The Qstream platform is also used by hundreds of leading brands in life sciences, technology, financial services and healthcare to reinforce learning and improve outcomes. To learn more, visit, or connect with us on Twitter.


Media Contact:

David Resendes
+1 (781) 205-4028